Loading organizations...
Loading organizations...

Octagos Health is a technology company.
Octagos Health has raised $52.0M across 2 funding rounds.
Octagos Health has raised $52.0M in total across 2 funding rounds.
Octagos is dedicated to transforming cardiac care through innovation, precision, and collaboration, empowering clinicians with tools for seamless and accessible patient care.
Octagos Health has raised $52.0M in total across 2 funding rounds.
Octagos Health's investors include Morgan Stanley, B Capital Group, Flourish Ventures, Mucker Capital, Tusk Venture Partners.
Octagos Health is a technology company specializing in advanced cardiac remote monitoring solutions. It builds an AI-driven platform that integrates data from a wide range of cardiac devices—including implantable pacemakers, defibrillators, ambulatory monitors, and heart failure tools—to provide continuous, real-time cardiac data analysis. The platform serves healthcare providers, particularly cardiologists and electrophysiologists, helping them manage large volumes of patient data efficiently, prioritize urgent cases, and improve patient outcomes through precise clinical and operational insights. Octagos simplifies cardiac care workflows, enhances clinical accuracy with AI-powered reports, and supports financial and operational analytics to optimize clinic performance[1][2][3][4][5].
Founded in 2020 by Dr. Shanti Bansal, a practicing cardiac electrophysiologist, Octagos Health emerged from his firsthand experience with the challenges of managing complex cardiac remote monitoring data. Dr. Bansal recognized the burden on clinicians caused by overwhelming data streams, inefficient reporting, and cumbersome technology. Motivated to improve this, he established Octagos to deliver cutting-edge tools that reduce clinician workload while maintaining clinical precision. Since its founding, the company has grown to about 111 employees and expanded its platform capabilities, including recent strategic investments in AI, product integration, and talent to broaden device compatibility and predictive analytics[2][3][4].
Octagos Health rides the growing trend of digital transformation in healthcare, particularly the shift toward remote patient monitoring (RPM) and AI-driven clinical decision support. The timing is critical as healthcare systems face increasing data volumes from diverse cardiac devices and demand more efficient, cost-effective care models. Octagos leverages AI to turn complex cardiac data into actionable insights, enabling proactive patient management and reducing hospitalizations. Its platform supports the broader ecosystem by integrating with electronic health records and expanding device compatibility, thus facilitating interoperability and data-driven care innovation. This positions Octagos as a key player in advancing precision cardiology and remote healthcare delivery[1][3][4][8].
Looking ahead, Octagos Health is poised to deepen its AI capabilities and expand its platform’s device integration further, including wearables and broader remote patient monitoring technologies. The company’s recent $43 million Series B funding and strategic hires, such as the new Chief Commercial Officer, signal strong growth momentum and ambition to lead in AI-powered cardiac care. Trends like personalized medicine, predictive analytics, and value-based care will shape Octagos’ journey, potentially increasing its influence in shaping how cardiac care is delivered globally. Its continued focus on simplifying clinician workflows while enhancing patient outcomes will likely drive adoption and innovation in the cardiac remote monitoring space[3][8].
In summary, Octagos Health exemplifies the fusion of clinical expertise and advanced AI technology to transform cardiac care, making it more precise, accessible, and efficient for providers and patients alike.
Octagos Health has raised $52.0M across 2 funding rounds. Most recently, it raised $43.0M Series B in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $43.0M Series B | Morgan Stanley | B Capital Group, Flourish Ventures, Mucker Capital, Tusk Venture Partners |
| May 1, 2023 | $9.0M Series A | B Capital Group, Flourish Ventures, Mucker Capital, Tusk Venture Partners |